All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the products second metabisulfite challenge.6

In for and cold 1992 in El Paso, TX a randomized, double-blind, products placebo controlled for study of subjects (n=130) with allergic rhinitis in cold 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average products IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) for returned a second set of symptom cold diaries which they had completed for days products 365 to 395 for (the same period, one year after the first set of symptom diaries). The active group had mean symptom cold scores showing products statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site for in 1993 were much higher than in 1992, cold leading to expectation of higher symptoms.)7

A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting to allergens such as animals, products mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is for a 21-day treatment of B12 lozenges cold sucked on twice daily. this medicationTM may help patients with products hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what for it is genetically capable of becoming, this medicationTM turns at least some allergic people into cold non-allergic or moderately-allergic people.